Literature DB >> 24871781

Preoperative characteristics of patients with presumed pancreatic cancer but ultimately benign disease: a multicenter series of 344 pancreatoduodenectomies.

Arja Gerritsen1, I Quintus Molenaar, Thomas L Bollen, C Yung Nio, Marcel G Dijkgraaf, Hjalmar C van Santvoort, G Johan Offerhaus, Lodewijk A Brosens, Katharina Biermann, Egbert Sieders, Koert P de Jong, Ronald M van Dam, Erwin van der Harst, Harry van Goor, Bert van Ramshorst, Bert A Bonsing, Ignace H de Hingh, Michael F Gerhards, Casper H van Eijck, Dirk J Gouma, Inne H M Borel Rinkes, Olivier R C Busch, Marc G Besselink.   

Abstract

BACKGROUND: Preoperative differentiation between malignant and benign pancreatic tumors can be difficult. Consequently, a proportion of patients undergoing pancreatoduodenectomy for suspected malignancy will ultimately have benign disease. The aim of this study was to compare preoperative clinical and diagnostic characteristics of patients with unexpected benign disease after pancreatoduodenectomy with those of patients with confirmed (pre)malignant disease.
METHODS: We performed a multicenter retrospective cohort study in 1,629 consecutive patients undergoing pancreatoduodenectomy for suspected malignancy between 2003 and 2010 in 11 Dutch centers. Preoperative characteristics were compared in a benign:malignant ratio of 1:3. Malignant cases were selected from the entire cohort by using a random number list. A multivariable logistic regression prediction model was constructed to predict benign disease.
RESULTS: Of 107 patients (6.6 %) with unexpected benign disease after pancreatoduodenectomy, 86 fulfilled the inclusion criteria and were compared with 258 patients with (pre)malignant disease. Patients with benign disease presented more often with pain (56 vs. 38 %; P = 0.004), but less frequently with jaundice (60 vs. 80 %; P < 0.01), a pancreatic mass (13 vs. 54 %, P < 0.001), or a double duct sign on computed tomography (21 vs. 47 %; P < 0.001). In a prediction model using these parameters, only 19 % of patients with benign disease were correctly predicted, and 1.4 % of patients with malignant disease were missed.
CONCLUSIONS: Nearly 7 % of patients undergoing pancreatoduodenectomy for suspected malignancy were ultimately diagnosed with benign disease. Although some preoperative clinical and imaging characteristics might indicate absence of malignancy, their discriminatory value is insufficient for clinical use.

Entities:  

Mesh:

Year:  2014        PMID: 24871781     DOI: 10.1245/s10434-014-3810-7

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  13 in total

1.  DNA flow cytometric analysis of paraffin-embedded tissue for the diagnosis of malignancy in bile duct biopsies.

Authors:  Hannah Lee; Peter S Rabinovitch; Aras N Mattis; Sanjay Kakar; Won-Tak Choi
Journal:  Hum Pathol       Date:  2020-04-06       Impact factor: 3.466

2.  Intraoperative Pancreatic Cancer Detection using Tumor-Specific Multimodality Molecular Imaging.

Authors:  Willemieke S Tummers; Sarah E Miller; Nutte T Teraphongphom; Adam Gomez; Idan Steinberg; David M Huland; Steve Hong; Sri-Rajasekhar Kothapalli; Alifia Hasan; Robert Ertsey; Bert A Bonsing; Alexander L Vahrmeijer; Rutger-Jan Swijnenburg; Teri A Longacre; George A Fisher; Sanjiv S Gambhir; George A Poultsides; Eben L Rosenthal
Journal:  Ann Surg Oncol       Date:  2018-04-17       Impact factor: 5.344

Review 3.  Comparative effectiveness of biliary brush cytology and intraductal biopsy for detection of malignant biliary strictures: a systematic review and meta-analysis.

Authors:  Udayakumar Navaneethan; Basile Njei; Vennisvasanth Lourdusamy; Rajesh Konjeti; John J Vargo; Mansour A Parsi
Journal:  Gastrointest Endosc       Date:  2014-11-01       Impact factor: 9.427

Review 4.  The Role of Endoscopic Ultrasound in Pancreatic Cancer Staging in the Era of Neoadjuvant Therapy and Personalised Medicine.

Authors:  Miguel Bispo; Susana Marques; Ricardo Rio-Tinto; Paulo Fidalgo; Jacques Devière
Journal:  GE Port J Gastroenterol       Date:  2020-09-07

5.  IgG4/IgG RNA ratio does not accurately discriminate IgG4-related disease from pancreatobiliary cancer.

Authors:  Elsemieke de Vries; Floor Tielbeke; Lowiek Hubers; Jeltje Helder; Nahid Mostafavi; Joanne Verheij; Jeanin van Hooft; Marc Besselink; Paul Fockens; Niek de Vries; Ulrich Beuers
Journal:  JHEP Rep       Date:  2020-04-14

6.  Ethanol-based fixation is superior to conventional brush cytology in the evaluation of indeterminate biliary strictures by endoscopic retrograde cholangiography.

Authors:  Martin Bürger; Antje Besser; Iver Petersen; Andreas Stallmach; Carsten Schmidt
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.889

7.  Selection of optimal molecular targets for tumor-specific imaging in pancreatic ductal adenocarcinoma.

Authors:  Willemieke S Tummers; Arantza Farina-Sarasqueta; Martin C Boonstra; Hendrica A Prevoo; Cornelis F Sier; Jan S Mieog; Johannes Morreau; Casper H van Eijck; Peter J Kuppen; Cornelis J van de Velde; Bert A Bonsing; Alexander L Vahrmeijer; Rutger-Jan Swijnenburg
Journal:  Oncotarget       Date:  2017-05-26

8.  Usefulness of Endoscopic Transpapillary Tissue Sampling for Malignant Biliary Strictures and Predictive Factors of Diagnostic Accuracy.

Authors:  Hiroki Tanaka; Shimpei Matsusaki; Youichirou Baba; Yoshiaki Isono; Tomohiro Sase; Hiroshi Okano; Tomonori Saito; Katsumi Mukai; Tetsuya Murata; Hiroki Taoka
Journal:  Clin Endosc       Date:  2017-08-31

9.  A rare non-oncological pancreatic mass: eosinophilic pancreatitis diagnosis through EUS-FNA.

Authors:  Diogo Turiani Hourneaux De Moura; Rodrigo Silva de Paula Rocha; José Jukemura; Vitor Ottoboni Brunaldi; Hugo Gonçalo Guedes; Franz Robert Apodaca Torrez; Igor Braga Ribeiro; Andres Gelrud; Eduardo Guimarães Hourneaux De Moura
Journal:  Endosc Int Open       Date:  2019-01-18

10.  Combined Expression of Plasma Thrombospondin-2 and CA19-9 for Diagnosis of Pancreatic Cancer and Distal Cholangiocarcinoma: A Proteome Approach.

Authors:  Tessa Y S Le Large; Laura L Meijer; Elisa Giovannetti; Geert Kazemier; Rosita Paleckyte; Lenka N C Boyd; Bart Kok; Thomas Wurdinger; Tim Schelfhorst; Sander R Piersma; Thang V Pham; Nicole C T van Grieken; Barbara M Zonderhuis; Freek Daams; Hanneke W M van Laarhoven; Maarten F Bijlsma; Connie R Jimenez
Journal:  Oncologist       Date:  2020-01-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.